Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

A once-daily oral GLP-1 conferred greater reductions in HbA1c and body weight than placebo among adults with type 2 diabetes, ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

while patients who were administered 36 mg doses lost 15.8 lbs, or 7.6% of their body weight. The drug also showed side effects similar to those of other GLP-1 drugs. Because many of the sales of ...